We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 02, 2021

Natalizumab, Fingolimod, and Dimethyl Fumarate and Pregnancy-Related Relapse and Disability in Multiple Sclerosis



Additional Info

Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Neurology 2021 Jun 15;96(24)e2989-e3002, WZ Yeh, PA Widyastuti, A Van der Walt, J Stankovich, E Havrdova, D Horakova, K Vodehnalova, S Ozakbas, S Eichau, P Duquette, T Kalincik, F Patti, C Boz, M Terzi, BI Yamout, J Lechner-Scott, P Sola, OG Skibina, M Barnett, M Onofrj, MJ Sá, PA McCombe, P Grammond, R Ampapa, F Grand'Maison, R Bergamaschi, DLA Spitaleri, V Van Pesch, E Cartechini, S Hodgkinson, A Soysal, A Saiz, M Gresle, T Uher, D Maimone, R Turkoglu, RM Hupperts, MP Amato, F Granella, C Oreja-Guevara, A Altintas, RA Macdonell, T Castillo-Trivino, H Butzkueven, R Alroughani, VG Jokubaitis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading